Full Year 2019 AXA SA Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kamran Hossain - RBC Capital Markets, Research Division - Analyst : It's Kamran Hossain from RBC. On results being going, I guess, we haven't hit Coronavirus yet. So let me just ask about that.

Question: Kamran Hossain - RBC Capital Markets, Research Division - Analyst : In terms of, I guess, being prepared for -- I think we can probably ignore the claims environment and -- due to Coronavirus. But if you look at SARS post that happening back in the early 2000s, there's a huge spike up in kind of health sales following that. How prepared are you to kind of take advantage of that? That's the first question. The next Q, sadly, are both on XL. Coming back to...

Question: Kamran Hossain - RBC Capital Markets, Research Division - Analyst : Coming back to the EUR 0.6 billion. To what extent are you already recognizing what you hope on margin improvements on long tail price improvements there? So we've seen claims inflation spike, to what extent do you think that doesn't happen again? And the second question is, that slide on cat exposures is fantastic. But I would expect that your cat, your kind of average nat cat number should probably come down because on the 1 in 5-year basis, it comes down quite a lot. So is the 4% nat cat number for AXA XL still the right one going forward?